Morgan Stanley vs Novartis AG: Strategic Comparison
Key Differences at a Glance
| Field | Morgan Stanley | Novartis AG |
|---|---|---|
| Revenue | $70.6B | $54.5B |
| Founded | 1935 | 1996 |
| Employees | 83,000 | 75,267 |
| Market Cap | $340.2B | $274.1B |
| Headquarters | United States | Switzerland |
Quick Stats Comparison
| Metric | Morgan Stanley | Novartis AG |
|---|---|---|
| Revenue | $70.6B | $54.5B |
| Founded | 1935 | 1996 |
| Headquarters | New York, New York, United States | Basel, Switzerland |
| Market Cap | $340.2B | $274.1B |
| Employees | 83,000 | 75,267 |
Morgan Stanley Revenue vs Novartis AG Revenue — Year by Year
| Year | Morgan Stanley | Novartis AG | Leader |
|---|---|---|---|
| 2025 | $70.6B | $54.5B | Morgan Stanley |
| 2024 | $61.8B | $50.3B | Morgan Stanley |
| 2023 | $54.1B | $45.4B | Morgan Stanley |
Business Model Breakdown
Overview: Morgan Stanley vs Novartis AG
This in-depth comparison examines Morgan Stanley and Novartis AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Morgan Stanley on its own, evaluating Novartis AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Morgan Stanley and Novartis AG is widest.
On the headline numbers, Morgan Stanley reports annual revenue of $70.6B against $54.5B for Novartis AG, while their respective market capitalizations stand at $340.2B and $274.1B. Morgan Stanley is headquartered in United States and Novartis AG operates from Switzerland, and those different home markets shape how each company competes.
Morgan Stanley: Morgan Stanley's biggest strategic shift is that the firm has made wealth management a ballast against volatile capital markets. That does not eliminate cyclicality, but it changes the earnings mix from pure Wall Street deal flow toward a broader client-asset platform.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Business Models: How Morgan Stanley and Novartis AG Make Money
Morgan Stanley and Novartis AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Morgan Stanley and Novartis AG.
Morgan Stanley business model: Morgan Stanley operates through Institutional Securities, Wealth Management, and Investment Management. Revenue comes from advisory fees, underwriting, trading, commissions, asset-based fees, net interest income, lending, brokerage, investment products, and asset management fees.
Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Competitive Advantage: Morgan Stanley vs Novartis AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Morgan Stanley stack up against those of Novartis AG.
Morgan Stanley competitive advantage: The firm combines a top-tier institutional franchise with a scaled wealth platform. That mix gives Morgan Stanley access to corporate clients, ultra-high-net-worth households, workplace stock-plan participants, self-directed traders, and institutional investors.
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Growth Strategy: Where Morgan Stanley and Novartis AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Morgan Stanley and Novartis AG each plan to expand from here.
Morgan Stanley growth strategy: Morgan Stanley's growth strategy emphasizes wealth and investment management scale, workplace and self-directed client acquisition, institutional cross-selling, international client growth, lending to wealth clients, capital-light fee revenue, and disciplined capital returns.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Financial Picture: Morgan Stanley vs Novartis AG
A closer look at the financial trajectory of Morgan Stanley and Novartis AG rounds out the comparison.
Morgan Stanley: For 2025, Morgan Stanley reported $70.645B in net revenues, $16.861B in net income, $10.21 diluted EPS, 21.6% ROTCE, and $1.420T in total assets. The year showed strong operating leverage as investment banking, trading, wealth management, and investment management all benefited from a healthier market backdrop.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
Company-Specific SWOT Notes
Morgan Stanley
The firm combines a top-tier institutional franchise with a scaled wealth platform.
Morgan Stanley wins by connecting institutional capital markets expertise with a massive wealth and investment management distribution platform.
The biggest risk is a sustained downturn in markets, dealmaking, or client activity that pressures both institutional revenue and wealth-management economics.
Morgan Stanley's growth strategy emphasizes wealth and investment management scale, workplace and self-directed client acquisition, institutional cross-selling, international client growth, lending to wealth clients, capital-light fee revenue, and disciplined capital returns.
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Morgan Stanley | Morgan Stanley reports the larger revenue base ($70.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Morgan Stanley | Founded in 1935 vs 1996. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Tied | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Morgan Stanley | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Morgan Stanley | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Morgan Stanley reports the larger revenue base ($70.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1935 vs 1996. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Morgan Stanley or Novartis AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Morgan Stanley vs Novartis AG
Is Morgan Stanley better than Novartis AG?
Verdict: Between Morgan Stanley and Novartis AG, Morgan Stanley is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Morgan Stanley comes out ahead in this Morgan Stanley vs Novartis AG comparison.
Who earns more — Morgan Stanley or Novartis AG?
Morgan Stanley earns more with $70.6B in annual revenue versus Novartis AG's $54.5B. Morgan Stanley leads on total revenue based on latest verified figures.
Which company has higher revenue — Morgan Stanley or Novartis AG?
Morgan Stanley reported $70.6B, while Novartis AG reported $54.5B. The revenue leader is Morgan Stanley based on latest verified figures.
Morgan Stanley revenue vs Novartis AG revenue — which is higher?
Morgan Stanley revenue: $70.6B. Novartis AG revenue: $54.5B. Morgan Stanley has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Morgan Stanley Annual Filings (10-K, 8-K)
- Morgan Stanley Corporate Website
- Morgan Stanley Annual Report 2025 - Revenue and Financial Data
- sec.gov
- morganstanley.com
- morganstanley.com
- data.sec.gov
- morganstanley.com
- ourhistory.morganstanley.com
- stockanalysis.com
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com